Growing research and patient accounts indicate that weight-loss drugs containing semaglutide or tirzepatide, such as Wegovy and Ozempic, can reduce cravings for alcohol and limit heavy drinking, though some users report social drawbacks.
Nearly 200 deaths and over 150,000 adverse reactions have been linked to anti-obesity drugs Mounjaro, Wegovy, Ozempic, and Saxenda in the UK, according to data from the MHRA Yellow Card scheme.
L&C Bio plans to launch MegaAdipoECM, an injectable skin booster made from donated human fat, targeting 'Ozempic face' and offering a biological alternative to silicone implants, set to launch in late 2027.
Elcella and Calocurb, natural supplements developed in the UK and NZ, respectively, aim to mimic synthetic diabetes medications' weight-loss effects by stimulating 'fullness hormones' GLP-1 and PYY, with promising but limited human trial results.
WuXi AppTec reported a 33.7 per cent rise in H1 net profit to 11.08 billion yuan, beating expectations driven by strong demand for weight-loss and diabetes drugs and US growth.
Wuxi AppTec, Asia's largest contract pharmaceutical research provider, reported H1 net income of 11.08 billion yuan, surpassing market estimates. This strong performance was driven by robust demand for weight-loss and diabetes drugs, alongside significant growth in its US business.
Growing demand for mini fridges for beauty products and GLP-1 medication is reshaping homes, driven by the wellness industry and weight-loss drugs. This trend spans luxury to budget markets, despite dermatological skepticism for most skincare products.
The "proteinmaxxing" trend and GLP-1 weight-loss medications are driving up demand for whey protein, a vital ingredient in infant formula. This has led to a 4.8% increase in UK formula prices, raising concerns about affordability for families and prompting calls for government-imposed price or profit caps.
US retail giants like Walmart, Costco, CVS, and Amazon are leveraging direct-to-consumer GLP-1 weight-loss drug programs to acquire long-term customer relationships, as employers increasingly drop coverage. This strategy aims to drive loyalty and cross-selling opportunities.
WuXi AppTec's Hong Kong-traded stock jumped 37% as major shareholders JPMorgan Chase, UBS Group, and BlackRock increased their stakes. The company is set to release its half-year earnings on August 3, with high market expectations.
Galderma CEO Flemming Ørnskov stated that the increased use of weight-loss drugs like Ozempic and Wegovy presents a "significant opportunity" for the aesthetics company, particularly in mitigating facial sagging. The company reported nearly 25% sales growth, with U.S. growth outpacing other regions at 32%.
Danish pharmaceutical giant Novo Nordisk is suing US-based Eli Lilly in a New Jersey court for "false and misleading" advertisements. Novo Nordisk alleges Eli Lilly used "outdated studies" to compare GLP-1 agonist drugs like Wegovy and Ozempic to Mounjaro and Zepbound, causing confusion.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
Novo Nordisk has filed a lawsuit in the US against Eli Lilly, accusing its rival of false advertising regarding the superiority of its weight-loss drugs, Mounjaro and Zepbound. Novo Nordisk claims Eli Lilly compared lower doses of Novo Nordisk's drugs with higher doses of its own, omitting newer options.
Two US biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, aiming to bring the blockbuster drug class into pet medicine amidst a growing pet obesity problem and increasing owner spending on pet health.
Weight-loss medications like Wegovy and Mounjaro are significantly altering UK consumer spending. Research indicates users spend less on groceries and eating out, shifting purchases towards healthier options and products that mitigate side effects, though spending patterns may revert upon cessation.
The once-a-day Wegovy weight-loss pill, containing semaglutide, is now available in UK high street and online pharmacies for private prescription. It is not yet available on the NHS. The pill offers a needle-free alternative to the jab but requires specific administration on an empty stomach.
The once-daily Wegovy weight loss pill, containing semaglutide, is now available privately in the UK, though not yet on the NHS. It works similarly to the injectable version by mimicking a gut hormone to reduce appetite and increase fullness, requiring a BMI of 30+ or 27-30 with weight-related conditions. Strict guidelines apply for taking the pill on an empty stomach, and costs range from £99 to £199 per month.
Nithin Kamath questions India's slow uptake of affordable GLP-1 weight-loss drugs despite rising obesity, citing challenges like long-term adherence and physician conservatism, prompting a cautionary response from Kiran Mazumdar-Shaw emphasizing diet and exercise for non-diabetic, non-obese individuals.
Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Zerodha co-founder Nithin Kamath attributes this to patient retention issues with weekly injections and conservative doctor prescribing habits. Oral alternatives may boost uptake, suggesting convenience, not price, will drive future acceptance.
Initial enthusiasm for India's generic weight-loss drugs is waning as domestic manufacturers revise sales targets downwards. Slower prescription growth, patient retention issues, and unexpected price cuts from the innovator are impacting adoption, leading to a cautious approach for new launches.
UPS is investing $48 million in 27 temperature-controlled facilities globally to meet the rising demand for GLP-1 weight-loss drugs and other sensitive medications, ensuring they remain within required temperature ranges for patient use.
Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare expenses in India. Most of these, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary, experts advise understanding policy exclusions and avoiding EMIs for elective treatments.
Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare spending in India. Most of these interventions, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary. Experts advise reviewing policy exclusions and avoiding EMIs for elective treatments.
